Should all platinum sensitive patients recieve PARP inhibitors?
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
The success of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)